Get the Stockscreener App
7.8752
6.05%
0.4352
Organon Co stock is traded at $7.8752, with a volume of 628.41K.
It is up +6.05% in the last 24 hours and up +10.50% over the past month.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
See More
Previous Close:
$7.44
Open:
$7.4
24h Volume:
628.41K
Relative Volume:
0.11
Market Cap:
$2.04B
Revenue:
$6.28B
Net Income/Loss:
$700.00M
P/E Ratio:
2.9252
EPS:
2.6922
Net Cash Flow:
$537.00M
1W Performance:
+10.66%
1M Performance:
+10.50%
6M Performance:
-20.78%
1Y Performance:
-49.03%
1-Day Range:
$7.39
$7.94
1-Week Range:
$7.08
$7.94
52-Week Range:
$6.18
$17.23
Organon Co Stock (OGN) Company Profile
Name
Organon Co
Sector
Industry
Phone
551-430-6000
Address
30 HUDSON STREET, JERSEY CITY
Compare OGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
7.86 | 1.93B | 6.28B | 700.00M | 537.00M | 2.6922 |
|
LLY
Lilly Eli Co
|
1,055.93 | 932.17B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
205.92 | 492.24B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
221.61 | 389.14B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
109.64 | 266.67B | 63.90B | 19.05B | 13.05B | 7.5596 |
|
NVS
Novartis Ag Adr
|
140.66 | 264.62B | 54.45B | 14.42B | 17.15B | 7.333 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Underweight |
| Oct-27-25 | Downgrade | Piper Sandler | Overweight → Underweight |
| May-02-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-06-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-03-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-21-23 | Initiated | Barclays | Overweight |
| Mar-16-23 | Initiated | Raymond James | Outperform |
| Oct-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-06-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Initiated | Piper Sandler | Neutral |
| Sep-01-21 | Initiated | BofA Securities | Buy |
| Jul-22-21 | Initiated | Citigroup | Buy |
| Jun-15-21 | Initiated | JP Morgan | Neutral |
| Jun-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-10-21 | Initiated | Evercore ISI | Outperform |
View All
Organon Co Stock (OGN) Latest News
Great week for Organon & Co. (NYSE:OGN) institutional investors after losing 51% over the previous year - simplywall.st
Organon (OGN) Surpasses Market Returns: Some Facts Worth Knowing - Yahoo Finance Australia
Samsung Bioepis Denies Organon Deal Rumors - Citeline News & Insights
Samsung Bioepis pursues direct sales by weighing Organon acquisition to boost profitsCHOSUNBIZ - Chosunbiz
Samsung Bioepis reviews Organon acquisition to boost direct biosimilar salesCHOSUNBIZ - Chosunbiz
Mixed Martial Arts Group Limited Stock Analysis and ForecastTechnical Resistance Breaks & Stay One Step Ahead of Risk Events - earlytimes.in
Organon & Co. (NYSE:OGN) Upgraded at Wall Street Zen - MarketBeat
Understanding the Setup: (OGN) and Scalable Risk - Stock Traders Daily
Will Organon Co 7XP stock outperform value peersMarket Growth Report & Fast Exit and Entry Trade Guides - moha.gov.vn
Volume Summary: How Organon Co stock reacts to inflationary pressuresBreakout Watch & Expert-Curated Trade Recommendations - moha.gov.vn
Does Organon’s 50% Share Price Slide Signal Opportunity in 2025? - Yahoo Finance
Gilman Hill Asset Management LLC Reduces Position in Organon & Co. $OGN - MarketBeat
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock - sharewise.com
Organon (OGN) Beats Stock Market Upswing: What Investors Need to Know - sharewise.com
Why (OGN) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Organon: Deep Value With No Clear Catalysts (NYSE:OGN) - Seeking Alpha
Pharma co Organon inks VPPA with Schneider Electric for solar in Spain - Renewables Now
Securities Lawsuit Alert: Organon & Co. (OGN)Contact Levi & Korsinsky Before July 22, 2025 - TMX Newsfile
Organon & Co. (NYSE:OGN) Given Average Recommendation of "Reduce" by Analysts - MarketBeat
OGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Organon & Co. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Organon pushes for sustainable investment in women’s health across Africa - The Business & Financial Times
TetraScience and Organon Collaborate to Modernize Quality Control Data Management - 富途牛牛
3 Healthcare Stocks with Questionable Fundamentals - The Globe and Mail
Organon Launches Phase 3 Study on Tapinarof Cream for Atopic Dermatitis in Infants - TipRanks
How Investors Are Reacting To Organon (OGN) As Barclays Joins Growing Analyst Skepticism - Sahm
Why Analysts See Organon’s Story Shifting Amid Governance Concerns And Lower Valuations - Yahoo Finance
Is Trending Stock Organon & Co. (OGN) a Buy Now? - Yahoo Finance
Organon & Co. $OGN Stake Lessened by Globeflex Capital L P - MarketBeat
Organon Shares Under Pressure Following Critical Analyst Review - AD HOC NEWS
Can Organon’s Steep 2025 Share Price Slide Signal a Long Term Opportunity? - simplywall.st
Organon pushes bold women’s health agenda at WHX Leaders’ Summit in Accra - MyJoyOnline
Les billets sont maintenant en vente pour Importance Vitale : sommet national sur la santé des femmes - GlobeNewswire Inc.
Why Organon (OGN) shares are trading lower today - MSN
New York State Common Retirement Fund Sells 353,330 Shares of Organon & Co. $OGN - MarketBeat
Understanding Momentum Shifts in (OGN) - news.stocktradersdaily.com
Investors in Organon & Co. (OGN): Protect Your RightsContact Levi & Korsinsky Before July 22, 2025 - ACCESS Newswire
Organon & Co. (NYSE:OGN) Stock Rating Upgraded by Barclays - MarketBeat
Organon & Co. $OGN Shares Bought by Cerity Partners LLC - MarketBeat
WHX Africa Leaders Summit: Organon Unveils Multi-Sector Approach to Women’s Health in Africa - News Ghana
Barclays Initiates Coverage of Organon (OGN) with Underweight Recommendation - Nasdaq
Why Organon (OGN) Shares Are Trading Lower Today - Finviz
Organon (OGN) Receives New Coverage with 'Underweight' Rating fr - GuruFocus
Barclays Initiates Coverage on Organon & Co. (NYSE:OGN) - MarketBeat
Norges Bank Takes $19.78 Million Position in Organon & Co. $OGN - MarketBeat
Organon initiated with an Underweight at Barclays - TipRanks
American Century Companies Inc. Grows Position in Organon & Co. $OGN - MarketBeat
What analysts say about Organon Co stockFederal Reserve Announcements & Outstanding Growth Strategies - earlytimes.in
A Closer Look At Organon & Co.'s (NYSE:OGN) Impressive ROE - 富途牛牛
Can Organon (OGN) Turn Rising Investor Attention Into a Durable Reboot of Its Core Story? - simplywall.st
Organon & Co. (OGN) Stock Forecasts - Yahoo! Finance Canada
Co. (7XP) stock compared to peersPortfolio Update Report & Precise Buy Zone Identification - Newser
Organon Co Stock (OGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):